Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Apr
18
Today In Oncology
Melanoma Can AI Enable Diagnosis Prediction
AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers
DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors
Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC
Romiplostim for Chemotherapy-Induced Thrombocytopenia
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo